ASP Isotopes Announces Strategic Collaboration with University of Bristol and Quantum Leap Energy for Advanced Lithium Laser Research Facility in the UK

Date: March 24, 2026
Ticker: NASDAQ: ASPI

Key Highlights for Investors

• Strategic Collaboration: ASP Isotopes Inc. (ASPI), through its wholly-owned subsidiary Quantum Leap Energy LLC (QLE), has commenced a major collaboration with the University of Bristol to design a state-of-the-art lithium laser enrichment research facility in the United Kingdom.
• Focus on Advanced Nuclear Fuels: The initiative targets the rapidly growing market for advanced nuclear fuels, with specific emphasis on lithium enrichment using cutting-edge laser technology.
• University-Led Feasibility Study: The University of Bristol will lead a four-month initial phase focused on comprehensive design and feasibility of a site-agnostic research facility, including detailed engineering, safety reviews, and technical specifications.
• Potential for New Facility Construction: Pending a successful feasibility assessment, the facility could move forward to construction at a University of Bristol site, enabling advanced research funded by QLE.
• Regulatory Engagement: QLE has engaged with UK government and regulatory bodies, including the Department for Energy Security and Net Zero, UK Atomic Energy Authority, Office for Nuclear Regulation, and the Environment Agency, demonstrating regulatory commitment and alignment with national nuclear strategy.
• Technology Platform: The project will leverage QLE’s proprietary Quantum Enrichment (QE) laser technology, originally developed for uranium isotope separation, now adapted for lithium enrichment with significant advantages over traditional methods.
• Market Opportunity: The enriched lithium-6 (6Li) and lithium-7 (7Li) are critical for both fusion and next-generation fission reactors. There is significant commercial demand due to fusion reactors requiring enrichment levels of 60-90% for lithium-6 compared to natural lithium’s 7.5% content.
• Strategic Partnerships: QLE has established industry partnerships with TerraPower, Fermi America, and the South African Nuclear Energy Corporation (Necsa) to accelerate commercialization of critical isotopes.
• ASPI’s Broader Strategy: ASP Isotopes is developing a differentiated isotope enrichment platform with facilities in Pretoria, South Africa, focusing on low atomic mass elements for use in nuclear medicine, semiconductors, and nuclear energy applications.

Detailed Overview of the Collaboration

Quantum Leap Energy LLC—a subsidiary dedicated to advancing innovative nuclear fuel cycle technologies—will work with the University of Bristol, leveraging the university’s expertise in research facility design, lithium handling, and safety. A multidisciplinary team will be assembled, including experts in mechanical, electrical, and plumbing design, structural engineering, architecture, project management, and laser safety.

The project will progress through several stages, culminating in RIBA Stage 4 (Technical Design) completion. This structured approach includes:

• Desk-based concept and feasibility analysis
• Detailed engineering and design specification
• Comprehensive documentation and safety assessments
• Development of facility cell design, with a focus on pyrophoric lithium handling and laser safety

Should the feasibility study yield positive results, construction of the facility will proceed at an off-campus University of Bristol site, with QLE funding the research. This step would significantly advance QLE’s commercial strategy, addressing supply constraints and supporting the UK’s nuclear innovation ecosystem.

Market & Regulatory Implications

• Regulatory Alignment: The project has been developed in ongoing consultation with key UK regulatory agencies, ensuring compliance with safety, security, and environmental standards. This proactive regulatory engagement could streamline future licensing and commercialization phases.
• Potentially Price Sensitive: The successful development and commercialization of advanced lithium enrichment technology could significantly enhance QLE and ASPI’s competitive position in the nuclear fuels market. Access to proprietary enrichment technologies, industry partnerships, and regulatory momentum may positively affect future revenues, contract opportunities, and overall market valuation.
• Strategic Positioning: With fusion and advanced fission technologies gaining global traction, the ability to supply enriched lithium isotopes at scale may become a critical bottleneck—and a lucrative revenue stream—for ASPI and its subsidiaries.

Forward-Looking Statements

Management cautions that statements relating to future plans, research and production activities, regulatory engagement, growth strategies, and commercialization are forward-looking and subject to risks and uncertainties. Actual results may differ materially due to factors outside the company’s control, including regulatory outcomes, technical feasibility, market demand, and other operational risks.

Contact Information

For investor relations, please contact: [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The article contains forward-looking statements which are subject to risks and uncertainties, and actual outcomes may differ materially.

View ASP Isotopes Inc. Historical chart here